Bausch + Lomb launches advanced Eye vitamin, target market expands to early-stage AMD
Bausch + Lomb (NYSE:BLCO) announced the commercial rollout of PreserVision AREDS3 in the United States, expanding its consumer health portfolio and adjusting its long-standing marketing strategy to capture patients in earlier stages of age-related macular degeneration (AMD).

_1402839_640x360_2500594243966-640x360.webp&w=3840&q=75)




_1402818_640x360_2500594755751-640x360.webp&w=3840&q=75)




